Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary AngioedemaFeener EP, Davie RL, Murugesan N, Pethen SJ, Hampton SL, Smith MD, Audhya PK, Yea CM
Drugs and Drug Candidates
Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activationClermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP
Frontiers in Pharmacology
Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstatCohn DM, Aygören-Pürsün E, Bernstein JA, Farkas H, Lumry WR, Maurer M, Zanichelli A, Iverson M, Hao J, Smith MD, Yea CM, Audhya PK, Riedl MA
2023 Clinical and Translation Allergy
Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On Demand Treatment for Hereditary AngiodemaDavie R, Edwards H, Evans D, Hodgson S, Stocks M, Smith A, Rushbrooke L, Pethen S, Roe M, Clark D, McEwan P, Hampton S
PMID: 36251573
Absorption, metabolism, and excretion of [14C]-sebetralstat (KVD900 following a single oral does in healthy male participantsMutch P, Bashir M, Jung B, Yi P, Iverson M
PMID: 36200371
KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study resultsMaetzel A, Smith MD, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Francombe D, Feener EP, Yea CM
PMID: 35086692
Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.
Duckworth EJ, Murugesan N, Li L, Rushbrooke LJ, Lee DK, De Donatis GM, Maetzel A, Yea CM, Hampton SL, Feener EP
Clinical & Experimental Allergy
One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B StudySun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.
OPHTHALMOLOGY RETINA
Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, and Feener EP.
Invest Ophthalmol Vis Sci. 2016; 57:2390-9.
PMID:27138737
Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP, Feener EP.
Diabetes. 2015; 64:3588-99.
PMID:25979073